This clinical trial investigates the combined effects of transcranial direct current stimulation (tDCS) and methylphenidate for treating cognitive dysfunction in Alzheimer's disease. The trial is being conducted at Mayo Clinic and represents an innovative approach combining non-invasive brain stimulation with pharmacological enhancement to potentially improve cognitive outcomes beyond either treatment alone.
The rationale for this combination approach stems from the understanding that both tDCS and methylphenidate can enhance cognitive function through different but potentially complementary mechanisms: tDCS modulates cortical excitability and neuroplasticity, while methylphenidate increases synaptic dopamine and norepinephrine availability[1].
| Field | Value |
|---|---|
| Trial ID | NCT07279740 |
| Phase | Phase 2 |
| Status | Recruiting |
| Location | Mayo Clinic (US) |
| Sponsor | Mayo Clinic |
| Participants | 12 |
| Study Design | Interventional, single-arm |
tDCS is a non-invasive brain stimulation technique that uses low-intensity direct current to modulate neuronal excitability[2]:
Physical Parameters:
Neurophysiological Effects:
Polarity-dependent modulation:
Neuroplasticity enhancement:
Network effects:
Target Regions in AD:
Typically, tDCS in AD targets:
Methylphenidate (Ritalin®, Concerta®) is a psychostimulant that increases dopamine and norepinephrine availability[3]:
Mechanism of Action:
Cognitive Effects:
Relevance to AD:
The combination of tDCS with methylphenidate may provide synergistic benefits:
Neurotransmitter enhancement: Methylphenidate increases catecholamines, potentially enhancing the synaptic changes induced by tDCS
Amplified neuroplasticity: Both interventions promote neuroplastic mechanisms that may be additive
Broader cognitive effects: Combining may improve multiple cognitive domains
Improved engagement: Methylphenidate may improve ability to participate in tDCS sessions
Evidence supports tDCS benefits in AD[4]:
Cognitive Outcomes:
Neuroimaging Findings:
Safety Profile:
Methylphenidate has been studied in various cognitive disorders:
AD-Specific Evidence:
Safety Considerations:
The theoretical basis for combination:
Intervention Schema:
Primary Endpoints:
Secondary Endpoints:
If successful, this trial could establish:
Results may inform:
| Adverse Event | Frequency |
|---|---|
| Skin irritation | 1-10% |
| Headache | 1-5% |
| Tingling sensation | Common (transient) |
| Fatigue | Rare |
| Adverse Event | Frequency |
|---|---|
| Appetite loss | 10-30% |
| Sleep disturbance | 10-20% |
| Headache | 5-15% |
| Mood changes | 5-10% |
tDCS for AD. Nat Rev Neurol. Nat Rev Neurol. 2023. ↩︎
Transcranial direct current stimulation. J Physiol. 2008. ↩︎
Methylphenidate for cognitive impairment. J Alzheimers Dis. 2022. ↩︎
Evidence-based guidelines on tDCS. Clin Neurophysiol. 2017. ↩︎